QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:ANIK

Anika Therapeutics - ANIK Stock Forecast, Price & News

$28.05
+0.55 (+2.00%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$27.50
$28.26
50-Day Range
$25.91
$32.10
52-Week Range
$19.95
$32.51
Volume
68,089 shs
Average Volume
84,323 shs
Market Capitalization
$410.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.6% Upside
$28.50 Price Target
Short Interest
Bearish
3.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.63mentions of Anika Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to ($0.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

918th out of 986 stocks

Surgical & Medical Instruments Industry

91st out of 100 stocks


ANIK stock logo

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Orthobiologics Market Share and Forecast till 2028
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Anika Therapeutics Earnings Preview
Anika Issues Statement
Caligan Partners Issues Open Letter to Anika Board
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings
11/04/2021
Today
3/23/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
297
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$28.50
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+1.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,860,000.00
Pretax Margin
-12.00%

Debt

Sales & Book Value

Annual Sales
$156.24 million
Cash Flow
$0.54 per share
Book Value
$19.55 per share

Miscellaneous

Free Float
14,190,000
Market Cap
$410.37 million
Optionable
Optionable
Beta
0.86

Social Links


Key Executives

  • Cheryl Renee Blanchard
    President, Chief Executive Officer & Director
  • Anne Nunes
    Vice President-Operations
  • Michael L. LevitzMichael L. Levitz
    Chief Financial Officer, Treasurer & EVP
  • Mira Leiwant
    VP-Quality, Regulatory & Clinical Affairs
  • Steven W. Ek
    Vice President-Research & Development













ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2023?

2 analysts have issued 1-year target prices for Anika Therapeutics' stock. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they anticipate the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 5.2% and is now trading at $28.05.
View the best growth stocks for 2023 here
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company earned $39.54 million during the quarter, compared to analysts' expectations of $36.45 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.43% and a negative net margin of 9.51%. During the same period in the prior year, the business earned ($0.45) earnings per share.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $168.40 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.57%), Renaissance Technologies LLC (4.08%), Caligan Partners LP (4.05%), Boothbay Fund Management LLC (2.52%), Geode Capital Management LLC (1.89%) and Portolan Capital Management LLC (1.42%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $28.05.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $410.37 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does Anika Therapeutics have?

The company employs 297 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 3/23/2023 by MarketBeat.com Staff